1. Home
  2. KROS vs FRPH Comparison

KROS vs FRPH Comparison

Compare KROS & FRPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KROS
  • FRPH
  • Stock Information
  • Founded
  • KROS 2015
  • FRPH 1986
  • Country
  • KROS United States
  • FRPH United States
  • Employees
  • KROS N/A
  • FRPH N/A
  • Industry
  • KROS Biotechnology: Pharmaceutical Preparations
  • FRPH Real Estate
  • Sector
  • KROS Health Care
  • FRPH Finance
  • Exchange
  • KROS Nasdaq
  • FRPH Nasdaq
  • Market Cap
  • KROS 589.8M
  • FRPH 608.6M
  • IPO Year
  • KROS 2020
  • FRPH N/A
  • Fundamental
  • Price
  • KROS $12.48
  • FRPH $29.71
  • Analyst Decision
  • KROS Buy
  • FRPH
  • Analyst Count
  • KROS 11
  • FRPH 0
  • Target Price
  • KROS $68.83
  • FRPH N/A
  • AVG Volume (30 Days)
  • KROS 1.4M
  • FRPH 23.4K
  • Earning Date
  • KROS 02-26-2025
  • FRPH 03-05-2025
  • Dividend Yield
  • KROS N/A
  • FRPH N/A
  • EPS Growth
  • KROS N/A
  • FRPH 45.62
  • EPS
  • KROS N/A
  • FRPH 0.40
  • Revenue
  • KROS $651,000.00
  • FRPH $31,414,000.00
  • Revenue This Year
  • KROS $303.39
  • FRPH N/A
  • Revenue Next Year
  • KROS N/A
  • FRPH N/A
  • P/E Ratio
  • KROS N/A
  • FRPH $73.17
  • Revenue Growth
  • KROS 8037.50
  • FRPH 4.04
  • 52 Week Low
  • KROS $12.22
  • FRPH $26.99
  • 52 Week High
  • KROS $73.00
  • FRPH $33.00
  • Technical
  • Relative Strength Index (RSI)
  • KROS 20.32
  • FRPH 44.40
  • Support Level
  • KROS $15.59
  • FRPH $28.58
  • Resistance Level
  • KROS $16.49
  • FRPH $30.02
  • Average True Range (ATR)
  • KROS 0.85
  • FRPH 0.63
  • MACD
  • KROS 1.00
  • FRPH -0.07
  • Stochastic Oscillator
  • KROS 5.01
  • FRPH 50.90

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

About FRPH FRP Holdings Inc.

FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, warehouse, and office buildings either alone or through joint ventures (the Development Segment); ownership, leasing and management of buildings through joint ventures (the Multifamily Segment).

Share on Social Networks: